Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial.
Eva Ciruelos GilPatricia VillagrasaTomás PascualMafalda OliveiraSonia PernasLaia ParéSantiago Escriva-de-RomaniLuis Manso SanchezBarbara AdamoE Martínez de DueñasJavier CortesSilvia VazquezAntonia PerellóIsabel GarauMireia MeléAlvaro MontañoBegoña BermejoSerafin Morales MurilloMaría J EcharriEstela VegaBlanca Gonzalez-FarrePatricia GalvánJordi CanesPaolo G NuciforoXavier GonzalezAleix PratPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Palbociclib in combination with trastuzumab is safe and exhibits promising survival outcomes in trastuzumab pretreated ER-positive/HER2-positive advanced breast cancer with a PAM50 Luminal A or B subtype. The enrollment was stopped prematurely, and a new randomized cohort was opened in this population.